NASDAQ:LUMO
Lumos Pharma Inc. Stock News
$2.45
-0.0491 (-1.96%)
At Close: May 24, 2024
Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript
03:10pm, Wednesday, 15'th May 2024
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
04:15pm, Tuesday, 14'th May 2024
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achiev
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
02:51pm, Thursday, 09'th May 2024
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quart
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
04:05pm, Thursday, 18'th Apr 2024
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
08:00am, Wednesday, 20'th Mar 2024
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t
Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript
05:45pm, Thursday, 07'th Mar 2024
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q4 2023 Earnings Conference March 7, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, IR Rick Hawkins - CEO and Chairman John McKew - President and
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
04:01pm, Thursday, 07'th Mar 2024
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Mo
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
09:00am, Monday, 26'th Feb 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
04:05pm, Monday, 05'th Feb 2024
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
04:05pm, Thursday, 04'th Jan 2024
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pituk
AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
04:05pm, Monday, 20'th Nov 2023
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Compan
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
09:47pm, Tuesday, 07'th Nov 2023
Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago.
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
04:35pm, Tuesday, 07'th Nov 2023
-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 –
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3